Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
18,01 USD | +5,94 % | -11,93 % | +198,67 % |
Kurzporträt
Mitarbeiterzahl: 50
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 03.01.20 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 01.01.21 |
Chief Tech/Sci/R&D Officer | - | - | |
Dewey McLin
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Randall Kaye
CTO | Chief Tech/Sci/R&D Officer | 62 | 21.03.22 |
Julie Baker
PRN | Corporate Officer/Principal | - | 01.01.23 |
Gus Cardenas
PRN | Corporate Officer/Principal | - | - |
Anne Danks
PRN | Corporate Officer/Principal | - | - |
Marco Peters
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 01.12.20 |
Director/Board Member | 68 | 01.12.20 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 01.02.20 |
Casey Lynch
BRD | Director/Board Member | 50 | 01.02.21 |
Kevin Lind
CEO | Chief Executive Officer | 47 | 03.01.20 |
Corinne Le Goff
BRD | Director/Board Member | 58 | 01.03.21 |
Jane Tiller
BRD | Director/Board Member | 59 | 15.11.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 2 420 755 | 0 | 0 | 92,22 % |
Aktie B | 1 | 33 607 490 | 33 226 030 ( 98,86 %) | 0 |
Unternehmenskontakt
Longboard Pharmaceuticals, Inc.
4275 Executive Square Suite 950
92037, La Jolla
+
http://www.longboardpharma.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+198,67 % | 661 Mio. | |
-3,30 % | 102 Mrd. | |
+1,79 % | 96,84 Mrd. | |
-0,44 % | 21,48 Mrd. | |
-18,35 % | 20,82 Mrd. | |
-7,45 % | 18,6 Mrd. | |
-40,31 % | 16,81 Mrd. | |
-26,84 % | 13,78 Mrd. | |
+0,59 % | 13,4 Mrd. | |
+20,86 % | 11,06 Mrd. |
- Börse
- Aktien
- A2QQZ6 Aktie
- Unternehmen Longboard Pharmaceuticals, Inc.